Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors

被引:6
作者
Ghosh, Arun K. [1 ,2 ]
Brindisi, Margherita [1 ,2 ]
机构
[1] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA
[2] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA
基金
美国国家卫生研究院;
关键词
cyclic ethers; drug discovery; HIV-1 protease inhibitors; Natural products; synthesis; IMMUNODEFICIENCY-VIRUS PROTEASE; ORALLY BIOAVAILABLE INHIBITOR; HIGH-AFFINITY P-2-LIGANDS; BIOLOGICAL EVALUATION; BIS-TETRAHYDROFURAN; CRYSTAL-STRUCTURE; RESISTANT HIV; X-RAY; LIGAND; RESOLUTION;
D O I
10.1002/ajoc.201800255
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
We have developed a conceptually new generation of non-peptidic HIV-1 protease inhibitors incorporating novel structural templates inspired by nature. This has resulted in protease inhibitors with exceptional potency and excellent pharmacological and drug-resistance profiles. The design of a stereochemically defined bis-tetrahydrofuran (bis-THF) scaffold followed by modifications to promote hydrogen bonding interactions with the backbone atoms of HIV-1 protease led to darunavir, the first clinically approved drug for treatment of drug resistant HIV. Subsequent X-ray crystal structure-based design efforts led us to create a range of exceptionally potent inhibitors incorporating other intriguing molecular templates possessing fused ring polycyclic ethers with multiple stereocenters. These structural templates are critical to inhibitors' exceptional potency and drug-like properties. Herein, we will highlight the synthetic strategies that provided access to these complex scaffolds in a stereoselective and optically active form, enabling our medicinal chemistry and drug development efforts.
引用
收藏
页码:1448 / 1466
页数:19
相关论文
共 113 条
[81]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690
[82]   NOVEL BINDING MODE OF HIGHLY POTENT HIV-PROTEINASE INHIBITORS INCORPORATING THE (R)-HYDROXYETHYLAMINE ISOSTERE [J].
KROHN, A ;
REDSHAW, S ;
RITCHIE, JC ;
GRAVES, BJ ;
HATADA, MH .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (11) :3340-3342
[83]  
Lemaire S. F. E., 2007, [No title captured], Patent No. [WO 2008055970 A2, 2008555970]
[84]   Drug Discovery and Natural Products: End of an Era or an Endless Frontier? [J].
Li, Jesse W. -H. ;
Vederas, John C. .
SCIENCE, 2009, 325 (5937) :161-165
[85]  
Matlin S. A., 2011, CHEM ELEMENT CHEM CO
[86]  
Mitsuya H, 2008, ADV PHARMACOL, V56, P169, DOI 10.1016/S1054-3589(07)56006-0
[87]   [4+2] Cycloaddition Reactions Catalyzed by a Chiral Oxazaborolidinium Cation. Reaction Rates and Diastereo-, Regio-, and Enantioselectivity Depend on Whether Both Bonds Are Formed Simultaneously [J].
Mukherjee, Santanu ;
Corey, E. J. .
ORGANIC LETTERS, 2010, 12 (05) :1024-1027
[88]   Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-2 [J].
Munoz-Torrero, Diego ;
Mangoni, Arduino A. ;
Liu, Hong ;
Hulme, Christopher ;
Rautio, Jarkko ;
Karaman, Rafik ;
de Sousa, Maria Emilia ;
Prokai-Tatrai, Katalin ;
Sabatier, Jean-Marc ;
Siciliano, Carlo ;
Javier Luque, F. ;
Kokotos, George ;
Ragno, Rino ;
Collina, Simona ;
Guillou, Catherine ;
Guetschow, Michael ;
Agrofoglio, Luigi A. .
MOLECULES, 2018, 23 (01)
[89]   Terpene trilactones from Gingko biloba:: From ancient times to the 21st century [J].
Nakanishi, K .
BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (17) :4987-5000
[90]  
Nakashima H, 2000, SYNTHESIS-STUTTGART, P817